BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32880915)

  • 1. Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy.
    Forde S; Matthews JD; Jahangiri L; Lee LC; Prokoph N; Malcolm TIM; Giger OT; Bell N; Blair H; O'Marcaigh A; Smith O; Kenner L; Bomken S; Burke GAA; Turner SD
    Br J Haematol; 2021 Jan; 192(2):354-365. PubMed ID: 32880915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study.
    Rigaud C; Auperin A; Jourdain A; Haouy S; Couec ML; Aladjidi N; Gandemer V; Lambliotte A; Plat G; Landman-Parker J; Michon J; Leblanc T; Patte C; Minard-Colin V
    Pediatr Blood Cancer; 2019 Sep; 66(9):e27873. PubMed ID: 31207026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
    Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
    BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
    Afify Z; Orjuela-Grimm M; Smith CM; Dalal M; Ford JB; Pillai P; Robles JM; Reddy S; McCormack S; Ehrhardt MJ; Ureda T; Alperstein W; Edington H; Miller TP; Rubinstein JD; Kavanaugh M; Bukowinski AJ; Friehling E; Rivers JM; Chisholm KM; Marks LJ; Mason CC
    Br J Haematol; 2023 Feb; 200(3):297-305. PubMed ID: 36454546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of 2016 WHO classification in the diagnosis of paediatric high-grade
    Zhang L; Brown LE; Bowen LM; McCarthy LC; Cooley LD; Repnikova E; Gener MA; Garola R; August KJ; Hays JA; Zwick DL; Li W
    J Clin Pathol; 2020 Sep; 73(9):563-570. PubMed ID: 31964683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
    Goldman S; Smith L; Galardy P; Perkins SL; Frazer JK; Sanger W; Anderson JR; Gross TG; Weinstein H; Harrison L; Shiramizu B; Barth M; Cairo MS
    Br J Haematol; 2014 Nov; 167(3):394-401. PubMed ID: 25066629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
    Zhang L; Nomie K; Zhang H; Bell T; Pham L; Kadri S; Segal J; Li S; Zhou S; Santos D; Richard S; Sharma S; Chen W; Oriabure O; Liu Y; Huang S; Guo H; Chen Z; Tao W; Li C; Wang J; Fang B; Wang J; Li L; Badillo M; Ahmed M; Thirumurthi S; Huang SY; Shao Y; Lam L; Yi Q; Wang YL; Wang M
    Clin Cancer Res; 2017 Aug; 23(15):4212-4223. PubMed ID: 28348046
    [No Abstract]   [Full Text] [Related]  

  • 9. Sequential karyotyping in Burkitt lymphoma reveals a linear clonal evolution with increase in karyotype complexity and a high frequency of recurrent secondary aberrations.
    Aukema SM; Theil L; Rohde M; Bauer B; Bradtke J; Burkhardt B; Bonn BR; Claviez A; Gattenlöhner S; Makarova O; Nagel I; Oschlies I; Pott C; Szczepanowski M; Traulsen A; Kluin PM; Klapper W; Siebert R; Murga Penas EM
    Br J Haematol; 2015 Sep; 170(6):814-25. PubMed ID: 26104998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.
    Sakarou M; Eisele L; Dührsen U; Hüttmann A
    Eur J Haematol; 2019 Mar; 102(3):241-250. PubMed ID: 30471148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL.
    Lee S; Luo W; Shah T; Yin C; O'Connell T; Chung TH; Perkins SL; Miles RR; Ayello J; Morris E; Harrison L; van de Ven C; Cairo MS
    Oncotarget; 2017 Apr; 8(17):27839-27853. PubMed ID: 28427156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma.
    Richter-Larrea JA; Robles EF; Fresquet V; Beltran E; Rullan AJ; Agirre X; Calasanz MJ; Panizo C; Richter JA; Hernandez JM; Roman-Gomez J; Prosper F; Martinez-Climent JA
    Blood; 2010 Oct; 116(14):2531-42. PubMed ID: 20570860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Burkitt lymphoma with a tumor cell-specific heptamethine carbocyanine-cisplatin conjugate.
    Mrdenovic S; Zhang Y; Wang R; Yin L; Chu GC; Yin L; Lewis M; Heffer M; Zhau HE; Chung LWK
    Cancer; 2019 Jul; 125(13):2222-2232. PubMed ID: 30840322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characteristics of terminal deoxynucleotidyl transferase negative precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.
    Yoon J; Yun JW; Jung CW; Ju HY; Koo HH; Kim SH; Kim HJ
    Genes Chromosomes Cancer; 2020 Apr; 59(4):255-260. PubMed ID: 31705772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients.
    Jakobsen LH; Ellin F; Smeland KB; Wästerlid T; Christensen JH; Jørgensen JM; Josefsson PL; Øvlisen AK; Holte H; Blaker YN; Grauslund JH; Bjørn J; Molin D; Lagerlöf I; Smedby KE; Colvin K; Thanarajasingam G; Maurer MJ; Habermann TM; Song KW; Zhu KY; Gerrie AS; Cheah CY; El-Galaly TC
    Br J Haematol; 2020 May; 189(4):661-671. PubMed ID: 32017050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and pathological features of Burkitt lymphoma showing expression of BCL2--an analysis including gene expression in formalin-fixed paraffin-embedded tissue.
    Masqué-Soler N; Szczepanowski M; Kohler CW; Aukema SM; Nagel I; Richter J; Siebert R; Spang R; Burkhardt B; Klapper W
    Br J Haematol; 2015 Nov; 171(4):501-8. PubMed ID: 26218299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and treatment outcomes of children and adolescents with aggressive mature B-cell lymphoma: a single-center analysis.
    Jeon W; Koh YK; Kang S; Kim H; Koh KN; Im HJ
    Blood Res; 2022 Mar; 57(1):41-50. PubMed ID: 35256548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The chick chorioallantoic membrane as an in vivo xenograft model for Burkitt lymphoma.
    Klingenberg M; Becker J; Eberth S; Kube D; Wilting J
    BMC Cancer; 2014 May; 14():339. PubMed ID: 24884418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low incidence of MYC/BCL2 double-hit in Burkitt lymphoma.
    Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Niino D; Ohshima K
    Pathol Int; 2015 Sep; 65(9):486-9. PubMed ID: 26182827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.